Protein Restriction (PR) for Weight Loss

NCT ID: NCT06263725

Last Updated: 2024-02-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prolonged dietary protein restriction has been shown to increase energy expenditure in mice simultaneously with an increase in plasma FGF21 levels. In overfeeding studies, a protein-restricted diet reduces weight gain in both mice and humans compared with normal and high-protein diets. Further, in energy balance studies, when lean men are provided with a protein-restricted diet for five weeks, an increase in energy intake was necessary to obtain their body weight. However, whether the effect of a protein-restricted diet is the same when consumed by overweight to obese men has divergent results in both mice and humans.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The present study is a randomised intervention study. Inclusion criteria for the study are healthy males age between 25 and 45 years, BMI between 26 and 32, low physical activity level (low aerobic capacity with a VO2 - peak of 30 ± 10 mL/min/kg), non-smoker, not using snuff, not suffering from diabetes, hypertension, or any daily medication use and a high dietary protein intake (≥1,5 g/kg body weight/day). Before the intervention period, the participants complete a two-week run-in period. The run-in period is designed to collect more detailed information about the participant's habitual diet, body weight, and physical activity pattern, as well as habituate the participants in the various tasks they have to complete during the intervention. Then a five-week intervention period is initiated where the participants are randomized to follow one of the following diets for 5 weeks: 1) a diet reduced in protein, replaced by primary carbohydrates (11 E% Protein, 50 E% carbohydrates, 37 E% fat), and 2) a control diet comprising habitual protein content (21E% Protein, 40 E% carbohydrates, 37 E% fat).

In the five-week intervention period, all food and drinks (besides water and coffee) are provided for the participant. All food is weighed to 1 gram of accuracy in meal portions for a seven-day cycle and is delivered to the participant.

During the intervention the volunteers participate in six test days, one every week during the intervention. 48 hours prior to the weekly test, the participants are asked to abstaine from vigorous physical activity. On all the test days, the participants arrive in the morning in a fasted state (no food or drink after 10 pm the night before) by passive transportation.

On the first test day (WT0), body composition is determined by DXA scan, and the total body water content is measured using bioimpedance analysis. Then resting metabolic rate is measured. Still, in the supine position, a blood sample is obtained from an antecubital vein. Biopsies are taken at baseline and at the end of the intervention (WT5). A fat biopsy is obtained from periumbilical subcutaneous adipose tissue and a muscle biopsy from the vastus lateralis muscle. On test day 3, halfway through the intervention, body composition, body water, and resting metabolic rate are measured, and blood is sampled from an antecubital vein. On week tests 1, 2, and 4, resting metabolic rate is measured, and blood sampled. At all visits to the institute, body weight is also measured.

During the intervention the participants wear a Sens motion sensor to monitor daily activity level.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diet, Healthy, Body Weight

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Restricted dietary protein

5 week intake of a isocaloric diet restricted in protein

Group Type EXPERIMENTAL

Restricted dietary protein

Intervention Type OTHER

Participants will be allocated to 5 week isocaloric restricted protein intake

Habitual diet

Intervention Type OTHER

Participants will be follow their habitual, high protein intake

Habitul diet

5 week intake of habitual, high protein diet

Group Type EXPERIMENTAL

Restricted dietary protein

Intervention Type OTHER

Participants will be allocated to 5 week isocaloric restricted protein intake

Habitual diet

Intervention Type OTHER

Participants will be follow their habitual, high protein intake

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Restricted dietary protein

Participants will be allocated to 5 week isocaloric restricted protein intake

Intervention Type OTHER

Habitual diet

Participants will be follow their habitual, high protein intake

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI between 26 and 32 Low physical activity level Non-smoker Not using snuff Not suffering from diabetes, hypertension, or any daily medication use High protein intake (≥1,5 g/kg body weight/day)

Exclusion Criteria

\-
Minimum Eligible Age

25 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Copenhagen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bente Kiens, D.Sci

Role: PRINCIPAL_INVESTIGATOR

University of Copenhagen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Copenhagen

Copenhagen, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ALyster

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.